Theralase Technologies Inc (TLTFF)

$0.12 0.00 (0.00%)

9:31 EDT TLTFF Stock Quote Delayed 30 Minutes

3 Innovative Biotech Stocks to Diversify Your Portfolio

By Sep 26, 2014

Echo Therapeutics (ECTE), Theralase Technologi (TLTFF) and Tribute Pharmaceuticals Canada (TBUFF) are biotech stocks to buy.

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 2,000

Day's Range $0.12 - $0.12

52-Week Range $0.11 - $0.24

Dividend & Yield N/A (N/A)

TLTFF Stock Predictions, Articles, and Theralase Technologies Inc News

From the Web

Theralase along with University of Manitoba to develop coronavirus vaccine and therapy (OTCMKTS:TLTFF)

From Seeking Alpha Aug 19, 2020

Theralase Technologies (OTCQX:TLTFF +25.2%) announced that it has executed a Sponsored Research Agreement with the University of Manitoba Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing Theralase's patented and proprietary PDCs.University of Manitoba’s will conduct experiments in conjunction with Theralase for the research and development of a coronavirus vaccine and therapeutic to be further evaluated in animal then human clinical testing in 2021.“Theralase has originated and fostered development of an advanced vaccine and therapy based on standardized anti-viral approaches by optimising its PDCs and anti-cancer technology platforms to prevent and fight enveloped viruses, including coronaviruses, such as COVID-19.

Theralase under pressure after update on study of bladder cancer treatment (OTCMKTS:TLTFF)

From Seeking Alpha Jul 30, 2020

Thinly traded nano cap Theralase Technologies (OTCQX:TLTFF -16.0%) is down on almost triple normal volume, albeit on turnover of only 290K shares, on the heels of preliminary data from a Phase 2 clinical trial evaluating a photodynamic therapy (PDT) in patients with non-muscle invasive bladder cancer (NMIBC) who have not responded to standard-of-care Bacillus Calmette-Guérin (a live attenuated strain of Mycobacterium bovis) treatment.The PDT consists of photosensitizer called TLD-1433, a compound that is highly toxic to bladder cancer cells, that is placed in the bladder and activated by a light source.58.3% (n=7/12) of treated patients responded by day 90 after the procedure, including three complete responders.In a bit of a hiccup, four patients (nonresponders) were removed from the study who experienced new T1 high-grade disease with or without carcinoma in situ (CIS), a type of NMIBC that has a higher risk of recurrence, at day 90, apparently per the study protocol at the time.

ADVERTISEMENT